Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?

Nephrology Dialysis Transplantation

Volumn 29, Issue 9, 2014, Pages 1710-1719

  Higashihara, Eiji ^a   Nutahara, Kikuo ^a   Tanbo, Mitsuhiro ^a   Hara, Hidehiko ^a   Miyazaki, Isao ^a   Kobayashi, Kuninori ^b   Nitatori, Toshiaki ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN UNIVERSITY   (Japan)

Author keywords

Autosomal dominant polycystic kidney disease; Glomerular filtration rate; Kidney volume; Urine volume; Vasopressin

Indexed keywords

COPEPTIN; CYSTATIN C; VASOPRESSIN; GLYCOPEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE COURSE; DIURESIS; FEMALE; FLUID INTAKE; GLOMERULUS FILTRATION RATE; HORMONE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MALE; PATIENT COMPLIANCE; PLASMA OSMOLALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SODIUM URINE LEVEL; URINALYSIS; URINE OSMOLALITY; URINE VOLUME; BLOOD; BLOOD PRESSURE; DRINKING; KIDNEY; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; YOUNG ADULT;

ADULT; BLOOD PRESSURE; DISEASE PROGRESSION; DRINKING; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY; MALE; MIDDLE AGED; ORGAN SIZE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; YOUNG ADULT;

EID: 84904552964     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu093     Document Type: Article

References (46)

1. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol 2000; 11: 1179-1187
2. Yamaguchi T, Pelling JC, Ramaswamy NT et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int 2000; 57: 1460-1471
3. Nagao S, Nishii K, Katsuyama M et al. Increased water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 2006; 17: 2220-2227
4. Wang X, Wu Y, Ward CJ et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008; 19: 102-108
5. Gattone VH, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326
6. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364
7. Higashihara E, Torres VE, Chapman AB et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011; 6: 2499-2507
8. Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl JMed 2012; 367: 2407-2418
9. Grantham JJ. Therapy for polycystic kidney disease? It's water, stupid! J Am Soc Nephrol 2008; 19: 1-2
10. Pei Y, Obaji J, Dupuis A et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol 2009; 20: 205-212
11. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1140-1150
12. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27: 58-65
13. Morgenthaler NG, Struck J, Alonso C et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119
14. Jaffe BM, Behrmann HR. Methods of Hormone Radioimmunoassays, 2nd edn. Academic Press, New York, NY: 1979
15. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992
16. Horio M, Imai E, Yasuda Y et al. Collaborators Developing the Japanese Equation for Estimated GFR. GFR estimation using standardized serum cystatin C in Japan. Am J Kidney Dis 2013; 61: 197-203
17. Orskov B, Borresen ML, Feldt-Rasmussen B et al. Estimating glomerular filtration rate using the new CKD-EPI equation and other equations in patients with autosomal dominant polycystic kidney disease. Am J Nephrol 2010; 31: 53-57
18. Chapman AB, Guay-Woodford LM, Grantham JJ et al. Renal structure in early autosomal dominant polycystic kidney disease (ADPKD): The consortium for radiologic imaging studies of polycystic kidney disease (CRISP) cohort. Kidney Int 2003; 64: 1035-1045
19. Higashihara E, Nutahara K, Okegawa T et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol 2014; 18: 157-165
20. Chapman AB, Bost JE, Torres VE et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479-486
21. Hebert LA, Greene T, Levey A et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962-971
22. Borghi L, Meschi T, Amato F et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. J Urol 1996; 155: 839-843
23. Barash I, Ponda MP, Goldfarb DS et al. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010; 5: 693-697
24. Wang CJ, Creed C, Winklhofer FT et al. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 2011; 6: 192-197
25. Halperin ML, Kamel KS, Goldstein MB. Fluid, electrolyte, and acid-base physiology, 4th edn. Saunders, Philadelphia, PA: 2010; 246-313
26. Kistler AD, Poster D, Krauer F et al. Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235-241
27. Meijer E, Bakker SJ, van der Jagt EJ et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2011; 6: 361-368
28. Meijer E, Boertien WE, Zietse R et al. Potential deleterious effects of vasopressin in chronic kidney disease and particularly autosomal dominant polycystic kidney disease. Kidney Blood Press Res 2011; 34: 235-244
29. Zittema D, Boertien WE, van Beek AP et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 2012; 7: 906-913
30. Boertien WE, Meijer E, Zittema D et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012; 27: 4131-4137
31. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1:148-157
32. Anastasio P, Cirillo M, Spitali L et al. Level of hydration and renal function in healthy humans. Kidney Int 2001; 60: 748-756
33. Berl T. Impact of solute intake on urine flow and water excretion. J Am Soc Nephrol 2008; 19: 1076-1078
34. Musch W, Xhaet O, Decaux G. Solute loss plays a major role in polydipsia-related hyponatraemia of both water drinkers and beer drinkers. QJM 2003; 96: 421-426
35. Martinez-Maldonado M, Yium JJ, Eknoyan G et al. Adult polycystic kidney disease: studies of the defect in urine concentration. Kidney Int 1972; 2:107-113
36. Higashihara E, Nutahara K, Tago K et al. Renal function studies in cystic renal diseases. Jpn J Nephrol 1981; 23: 1021-1026
37. Irazabal MV, Torres VE, Hogan MC et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011; 80: 295-301
38. Torres VE, Grantham JJ, Chapman AB et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011; 6: 640-647
39. Torres VE, King BF, Chapman AB et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2007; 2: 112-120
40. Klahr S, Breyer JA, Beck GJ et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of diet in renal disease study group. J Am Soc Nephrol 1995; 5: 2037-2047
41. Bagrov AY, Shapiro JI, Fedorova OV. Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. Pharmacol Rev 2009; 61: 9-38
42. Manunta P, Hamilton BP, Hamlyn JM. Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. Am J Physiol Regul Integr Comp Physiol 2006; 290: R553-R559
43. Sanders PW. Vascular consequences of dietary salt intake. Am J Physiol Renal Physiol 2009; 297: F237-F243
44. Nguyen AN, Wallace DP, Blanco G. Ouabain binds with high affinity to the Na, K-ATPase in human polycystic kidney cells and induces extracellular signal-regulated kinase activation and cell proliferation. J Am Soc Nephrol 2007; 18: 46-57
45. Jansson K, Nguyen AN, Magenheimer BS et al. Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways. Am J Physiol Renal Physiol 2012; 303: F982-F990
46. Wang D, Iversen J, Wilcox CS et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388